Terns Pharmaceuticals
Executive Summary
Terns Pharmaceuticals is a dual-HQ biotech company (Foster City/Shanghai) with clear BIOSECURE status, making it a viable partner for US pharma deals. The company appears to maintain operations in both US and China, which could provide strategic advantages for global development programs. Recent 10-K filing suggests active SEC reporting and corporate governance compliance, indicating institutional-grade deal readiness.
Structure: As a US-listed biotech with dual headquarters in Foster City and Shanghai, Terns likely operates through a traditional holding company structure rather than a VIE arrangement, given its clear BIOSECURE status. The 10-K filing mentions VIE disclosures, suggesting the company may have evaluated or previously used VIE structures but has since restructured to maintain compliance with US regulatory requirements.
Ownership & Shareholder Structure
Terns Pharmaceuticals → Eli Lilly
Terns NASH/metabolic pipeline competes in Lilly metabolic market.
Corporate Events
Terns Pharmaceuticals 10-K Annual Report
10-K annual report filed with SEC. Contains corporate structure, VIE disclosures, and risk factors.
BIOSECURE Risk
Company has clear BIOSECURE status and is not designated under BCC categories, indicating successful navigation of US regulatory compliance requirements
Key Exposures:
- •Dual China operations could create future regulatory scrutiny
- •Supply chain dependencies in China may require monitoring
Mitigation: Company appears to have proactively addressed BIOSECURE compliance through corporate restructuring and maintains clear status
BD Intelligence
Therapeutic Areas:
Recent Deals: No recent deal activity identified in available data
Approach: Approach with standard due diligence protocols; low regulatory risk profile makes this an attractive potential partner for US pharma seeking China market access or development capabilities
Red Flags
- ⚠Limited public information on key personnel and pipeline assets
- ⚠Dual HQ structure requires verification of operational control and IP ownership
- ⚠Recent 10-K filing suggests potential corporate structure changes that need review
Quick Facts
- Key People
- 0
- Subsidiaries
- 0
- CDMO/CRO Subs
- 0
- Genomics Subs
- 0
- Direct BIOSECURE
- 0
- Corp Events
- 1
- Gov-Connected
- 0
- Clinical Trials
- 0
- Publications
- 0
- Drug Molecules
- 0
- Relationships
- 1
Sources & Methodology
Clinical trials data: ClinicalTrials.gov API v2 (0 trials linked to this entity)
SEC BIOSECURE filings: EDGAR EFTS full-text search (850+ filings from 230 companies)
Publications: Europe PMC API (0 publications indexed)
Drug molecules: ChEMBL database (European Bioinformatics Institute)
Financial data: East Money (东方财富) datacenter API / CNINFO (巨潮资讯网)
Corporate structure: Company official filings, HKEX/SSE/SZSE disclosures
Executive profiles: Company official biographies, SEC filings, LinkedIn (where verified)
Data is collected from public sources and updated weekly. Corporate intelligence is verified by a native Mandarin-speaking analyst against Chinese-language primary sources including Tianyancha (天眼查), GSXT (国家企业信用信息公示系统), and CNINFO (巨潮资讯网). This is not financial or legal advice.